MiraLAX vs Metamucil: Key Differences
MiraLAX (polyethylene glycol 3350) is an osmotic laxative that works by drawing water into the colon, while Metamucil (psyllium) is a soluble fiber supplement that increases stool bulk by trapping water—they have different mechanisms, efficacy profiles, and clinical roles in treating constipation.
Mechanism of Action
- MiraLAX (PEG 3350) is a long-chain polymer of ethylene oxide that functions as an osmotic laxative, drawing water into the intestinal lumen to soften stool 1
- Metamucil (psyllium) is a soluble fiber that traps water in the intestine and increases stool bulk, promoting peristalsis 1
Clinical Efficacy
MiraLAX Performance
- PEG 3350 has moderate-quality evidence showing it increases complete spontaneous bowel movements by 2.90 per week compared to placebo 1
- Increases spontaneous bowel movements by 2.30 per week based on meta-analysis of three trials 1
- 42% of patients meet FDA responder criteria (≥3 complete bowel movements/week with ≥1 increase from baseline for ≥9/12 weeks) compared to 13% with placebo 2
- Efficacy is durable over 6 months of continuous use 1
Metamucil (Psyllium) Performance
- Psyllium has low-quality evidence with only conditional recommendation for use 1
- Among fiber supplements evaluated, only psyllium appears effective, though data is limited 1
- Direct comparison shows PEG 3350 is significantly more effective than psyllium: normalized stools in 87.3% vs 66.7% of patients (p<0.001) 3
- PEG 3350 achieved mean weekly defecation rate of 8.48 vs 5.71 for psyllium after 2 weeks 3
Strength of Recommendations
- MiraLAX receives a STRONG recommendation from the American Gastroenterological Association/American College of Gastroenterology with moderate certainty of evidence 1
- Metamucil receives only a CONDITIONAL recommendation with low certainty of evidence 1
Treatment Algorithm Position
- Psyllium (Metamucil) can be used as first-line therapy for mild chronic idiopathic constipation, particularly in patients with low dietary fiber intake 1
- PEG 3350 (MiraLAX) should be used earlier in the treatment algorithm, either after a trial of fiber supplementation or in combination with fiber 1
- For patients requiring more robust treatment, PEG 3350 is the preferred agent given its superior efficacy 1
Dosing
- MiraLAX: 17 g once daily mixed in 8 ounces of liquid 1, 4
- Metamucil: 14 g per 1,000 kcal of daily intake, typically taken with 8-10 ounces of fluid 1
Side Effect Profiles
MiraLAX Side Effects
- Abdominal distension, loose stool, flatulence, and nausea 1
- Diarrhea occurs more commonly (158 more per 1,000 patients) 1
- Most adverse events are mild to moderate and decrease markedly after the first week of treatment 2
- No serious adverse events conclusively linked to PEG 3350 1
Metamucil Side Effects
- Flatulence is the most commonly observed side effect 1
- Bloating and abdominal discomfort can occur, especially if inadequate hydration 1
Important Clinical Considerations
For MiraLAX
- FDA-approved only for occasional constipation, but evidence supports efficacy in chronic idiopathic constipation for up to 6 months 1
- Widely available over-the-counter and relatively inexpensive (estimated $10-$45 monthly) 1
- No clear maximum dose; can be titrated based on symptom response 1
For Metamucil
- Adequate hydration is essential when using fiber supplements to prevent worsening constipation 1
- Dietary assessment should determine total fiber intake from diet and supplements before initiating 1
- Cost is typically less than $50 monthly 1
Common Pitfalls
- Do not use psyllium without ensuring adequate fluid intake, as this can paradoxically worsen constipation 1
- PEG 3350 is often incorrectly thought to be only for short-term use, but evidence supports sustained efficacy over 6 months 1
- Patients may experience initial gastrointestinal symptoms with PEG 3350, but these typically resolve after the first week 2
- Psyllium may cause significant flatulence, which can limit tolerability in some patients 1